FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2152737868> ?p ?o ?g. }

• W2152737868 endingPage "434" @default.
• W2152737868 startingPage "425" @default.
• W2152737868 abstract "Purpose To predict survival in patients with metastatic melanoma by evaluating a combination of serum lactate dehydrogenase (LDH) level and initial computed tomographic (CT) findings of tumor devascularization after antiangiogenic therapy. Materials and Methods Consent was waived for this institutional review board–approved, retrospective, secondary analysis. Forty-four patients with metastatic melanoma received bevacizumab therapy in a randomized prospective phase II trial. Target lesions on the initial posttherapy CT images were evaluated by using Response Evaluation Criteria in Solid Tumors, the Choi criteria, and Morphology, Attenuation, Size, and Structure (MASS) criteria. Cox proportional hazards models were used to assess the association of baseline clinical variables including serum LDH and imaging findings with progression-free and overall survival. The receiver operating characteristic curve with area under the curve (AUC) was used to evaluate accuracy. Results In multivariate analysis, a high baseline serum LDH level was associated with decreased progression-free survival (hazard ratio = 1.29 for each increase of 100 IU/L; P = .002) and overall survival (hazard ratio = 1.44 for each increase of 100 IU/L; P = .001). Evaluation with MASS criteria of the first CT examination after therapy strongly predicted progression-free (P < .001) and overall (P < .001) survival. Baseline serum LDH level was moderately accurate for predicting progression-free survival at 9 months (AUC = 0.793) and overall survival at 18 months (AUC = 0.689). The combination of baseline serum LDH levels and evaluation with MASS criteria at the first CT examination after therapy had significantly higher accuracy for predicting progression-free survival at 9 months (AUC = 0.969) and overall survival at 18 months (AUC = 0.813) than did baseline serum LDH levels alone for prediction of progression-free survival (P = .020). Conclusion A combination of baseline serum LDH levels and evaluation with MASS criteria at the first CT examination after bevacizumab therapy had the highest accuracy for predicting survival in patients with metastatic melanoma. © RSNA, 2013 Online supplemental material is available for this article." @default.
• W2152737868 created "2016-06-24" @default.
• W2152737868 creator A5003989600 @default.
• W2152737868 creator A5007950766 @default.
• W2152737868 creator A5010788589 @default.
• W2152737868 creator A5034401006 @default.
• W2152737868 creator A5060897770 @default.
• W2152737868 creator A5073568638 @default.
• W2152737868 creator A5081220636 @default.
• W2152737868 date "2014-02-01" @default.
• W2152737868 modified "2023-10-04" @default.
• W2152737868 title "Metastatic Melanoma: Lactate Dehydrogenase Levels and CT Imaging Findings of Tumor Devascularization Allow Accurate Prediction of Survival in Patients Treated with Bevacizumab" @default.
• W2152737868 cites W1985126174 @default.
• W2152737868 cites W1997928510 @default.
• W2152737868 cites W1998005755 @default.
• W2152737868 cites W2019607817 @default.
• W2152737868 cites W2035337464 @default.
• W2152737868 cites W2043215134 @default.
• W2152737868 cites W2099465542 @default.
• W2152737868 cites W2107464631 @default.
• W2152737868 cites W2109242212 @default.
• W2152737868 cites W2115113482 @default.
• W2152737868 cites W2118320294 @default.
• W2152737868 cites W2118863192 @default.
• W2152737868 cites W2123534406 @default.
• W2152737868 cites W2139020082 @default.
• W2152737868 cites W2145473922 @default.
• W2152737868 cites W2150106670 @default.
• W2152737868 cites W2163890909 @default.
• W2152737868 doi "https://doi.org/10.1148/radiol.13130776" @default.
• W2152737868 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3985552" @default.
• W2152737868 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24072776" @default.
• W2152737868 hasPublicationYear "2014" @default.
• W2152737868 type Work @default.
• W2152737868 sameAs 2152737868 @default.
• W2152737868 citedByCount "23" @default.
• W2152737868 countsByYear W21527378682014 @default.
• W2152737868 countsByYear W21527378682015 @default.
• W2152737868 countsByYear W21527378682016 @default.
• W2152737868 countsByYear W21527378682017 @default.
• W2152737868 countsByYear W21527378682019 @default.
• W2152737868 countsByYear W21527378682020 @default.
• W2152737868 countsByYear W21527378682021 @default.
• W2152737868 countsByYear W21527378682022 @default.
• W2152737868 crossrefType "journal-article" @default.
• W2152737868 hasAuthorship W2152737868A5003989600 @default.
• W2152737868 hasAuthorship W2152737868A5007950766 @default.
• W2152737868 hasAuthorship W2152737868A5010788589 @default.
• W2152737868 hasAuthorship W2152737868A5034401006 @default.
• W2152737868 hasAuthorship W2152737868A5060897770 @default.
• W2152737868 hasAuthorship W2152737868A5073568638 @default.
• W2152737868 hasAuthorship W2152737868A5081220636 @default.
• W2152737868 hasBestOaLocation W21527378682 @default.
• W2152737868 hasConcept C10515644 @default.
• W2152737868 hasConcept C126322002 @default.
• W2152737868 hasConcept C141071460 @default.
• W2152737868 hasConcept C143998085 @default.
• W2152737868 hasConcept C181199279 @default.
• W2152737868 hasConcept C185592680 @default.
• W2152737868 hasConcept C207103383 @default.
• W2152737868 hasConcept C2776694085 @default.
• W2152737868 hasConcept C2777106319 @default.
• W2152737868 hasConcept C2777318727 @default.
• W2152737868 hasConcept C2777802072 @default.
• W2152737868 hasConcept C2779984678 @default.
• W2152737868 hasConcept C2780739268 @default.
• W2152737868 hasConcept C2989005 @default.
• W2152737868 hasConcept C31760486 @default.
• W2152737868 hasConcept C44249647 @default.
• W2152737868 hasConcept C50382708 @default.
• W2152737868 hasConcept C55493867 @default.
• W2152737868 hasConcept C58471807 @default.
• W2152737868 hasConcept C71924100 @default.
• W2152737868 hasConcept C76318530 @default.
• W2152737868 hasConceptScore W2152737868C10515644 @default.
• W2152737868 hasConceptScore W2152737868C126322002 @default.
• W2152737868 hasConceptScore W2152737868C141071460 @default.
• W2152737868 hasConceptScore W2152737868C143998085 @default.
• W2152737868 hasConceptScore W2152737868C181199279 @default.
• W2152737868 hasConceptScore W2152737868C185592680 @default.
• W2152737868 hasConceptScore W2152737868C207103383 @default.
• W2152737868 hasConceptScore W2152737868C2776694085 @default.
• W2152737868 hasConceptScore W2152737868C2777106319 @default.
• W2152737868 hasConceptScore W2152737868C2777318727 @default.
• W2152737868 hasConceptScore W2152737868C2777802072 @default.
• W2152737868 hasConceptScore W2152737868C2779984678 @default.
• W2152737868 hasConceptScore W2152737868C2780739268 @default.
• W2152737868 hasConceptScore W2152737868C2989005 @default.
• W2152737868 hasConceptScore W2152737868C31760486 @default.
• W2152737868 hasConceptScore W2152737868C44249647 @default.
• W2152737868 hasConceptScore W2152737868C50382708 @default.
• W2152737868 hasConceptScore W2152737868C55493867 @default.
• W2152737868 hasConceptScore W2152737868C58471807 @default.
• W2152737868 hasConceptScore W2152737868C71924100 @default.
• W2152737868 hasConceptScore W2152737868C76318530 @default.
• W2152737868 hasIssue "2" @default.
• W2152737868 hasLocation W21527378681 @default.
• W2152737868 hasLocation W21527378682 @default.

• next